#type2diabetes Tag

07 Jun

Posted at 00:31h in Author Interviews, Diabetes, Technology
MedicalResearch.com Interview with: [caption id="attachment_74111" align="alignleft" width="92"]Luis A. Rodriguez, PhD, MPH, RDResearch Scientist, Kaiser Permanente Northern California Division of Research Assistant Professor, Department of Health System Sciences Kaiser Permanente Bernard J. Tyson School of Medicine Assistant Adjunct Professor, Department of Epidemiology & Biostatistics University of California, San Francisco Dr. Rodriguez[/caption] Luis A. Rodriguez, PhD, MPH, RD Research Scientist, Kaiser Permanente Northern California Division of Research Assistant Professor, Department of Health System Sciences Kaiser Permanente Bernard J. Tyson School of Medicine Assistant Adjunct Professor, Department of Epidemiology & Biostatistics University of California, San Francisco ADA 2026 Poster Presentation: Machine-Learning Modeling for T2DM Prediction in over 3 Million Adults American Diabetes Association 85th Scientific Sessions, June 2026
MedicalResearch.com: What is the background for this study? What are the risk factors used to develop the prediction model? Response: Type 2 diabetes develops gradually over many years, often without clear warning signs. As a result, it can be difficult for health systems to identify which adults are most likely to benefit from prevention efforts before the disease develops. In this study, we used electronic health record data from more than 3 million adults in Kaiser Permanente Northern California to develop a prediction model that estimates an individual's risk of developing type 2 diabetes over 1, 3, and 10 years. The model is based on information routinely collected during clinical care, including age, sex, race/ethnicity, body mass index, blood glucose levels, smoking, physical activity, medical and family history, and medication use. By combining these clinical, biological and behavioral factors, the model provides a more comprehensive assessment of diabetes risk than traditional screening approaches.

13 May

Posted at 15:50h in Breast Cancer, Cancer Research, JAMA, Weight Research
MedicalResearch.com Interview with: [caption id="attachment_73639" align="alignleft" width="125"]Bernard F. Fuemmeler, PhD, MPHProfessor and Gordon D. Ginder, MD Chair in Cancer Research Associate Director of Population Science, Massey Comprehensive Cancer Center Director of Research, Family Medicine and Population Health Dr. Fuemmeler[/caption] Bernard F. Fuemmeler, PhD, MPH Professor and Gordon D. Ginder, MD Chair in Cancer Research Associate Director of Population Science, Massey Comprehensive Cancer Center Director of Research, Family Medicine and Population Health [caption id="attachment_73640" align="alignleft" width="125"]Kristina L. Tatum, PsyD, MSInstructor Department of Social and Behavioral Sciences School of Public Health Dr. Tatum[/caption] Kristina L. Tatum, PsyD, MS Instructor Department of Social and Behavioral Sciences School of Public Health A large population-based analysis of more than 841,000 breast cancer patients across the United States examines whether GLP-1 receptor agonist use is associated with improved survival and lower recurrence risk — with findings that researchers describe as very promising.
MedicalResearch.com: What is the background for this study? What are the main findings? Response: Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used since 2005 and as the GLP1RAs treatments and delivery methods have improved, their use has markedly increased. Now it is estimated that nearly 1 in 8 US adults report ever using a GLP-1RA, which includes many people who are using them to treat obesity, diabetes, heart disease, and sleep apnea. There has been some preclinical data from mouse models to suggest that maybe GLP1RAs have an anticancer effect reducing the effects of obesity on tumor growth or progression. We were interested to understand to what extent GLP1RA use among cancer patients might be associated with cancer outcomes, like length of survival after cancer treatment or the chance of recurrence. In our large population-based study using an aggregate of de-identified electronic health record data from more than 841,000 patients with breast cancer across the US, we found that GLP-1 RAs use was associated with significantly improved survival and lower recurrence risk among patients with obesity or type 2 diabetes. Among patients with obesity, GLP-1 RAs use was associated with approximately 65% lower risk of death and a 56% lower risk of recurrence over 10 years compared with nonuse. We also observed substantially improved outcomes among patients with type 2 diabetes compared with insulin or metformin.